PARP1 and neoplasm: The response of BRCA1 mutation-associated cancers to both PARP inhibitors and cisplatin-based chemotherapeutic agents has driven the interest in identifying tumours with a similar DNA-repair deficient phenotype, so that these difficult to treat patients might also benefit from targeted therapies.